BRAIN and NERVE－神経研究の進歩66巻5号

2014年05月発行

特集 アセチルコリンと神経疾患―100年目の現在地

重症筋無力症とアセチルコリン

著者： 藤岡俊樹¹

所属機関： ¹東邦大学医学部内科学講座神経内科学分野（大橋）

ページ範囲：P.517 - P.525

文献概要

アセチルコリン分子の流れである神経筋接合部での生理機能と，その破綻をきたす疾患である重症筋無力症のメカニズム・症状・治療法などを概説した。当初は，神経筋伝達物質であるアセチルコリンの作用増強を中心にした治療が発達したが，免疫学の発達によりアセチルコリン受容体の障害機序が明らかになり，現在はそれを引き起こす免疫異常の是正が注目されている。今後は遺伝子治療や分子標的治療が主体となると予想される。

参考文献

1) Purves D, Augustine GJ, Fitzpatrick D, Hall WC, LaMantia AS, et al: Neuroscience. 5th ed. Sinauer Associates, Inc, Sunderland, 2012

2) Schafer MK, Eiden LE, Weihe E: Cholinergic neurons and terminal fields revealed by immunohistochemistry for the vesicular acetylcholine transporter. II. the peripheral nervous system. Neuroscience 84: 361-376, 1998

3) Sutton RB, Fasshauer D, Jahn R, Brunger AT: Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution. Nature 395: 347-353, 1998

4) Heuser JE, Reese TS: Evidence for recycling of synaptic vesicle membrane during transmitter release at the frog neuromuscular junction. J Cell Biol 57: 315-344, 1973

5) Conti-Fine BM, Milani M, Kaminski HJ: Myasthenia gravis: past, present, and future. J Cin Invest 116: 2843-2854, 2006

6) Richmond JE Jorgensen EM: One GABA and two acetylcholine receptors function at the C. elegans neuromuscular junction. Nat Neurosci 2: 791-797, 1999

7) Asherwood PNR Machili P: Pharmacological properties of excitatory neuromuscular synapses in the locust. J Exp Biol 49: 341-361, 1968

8) Eiden LE: The cholinergic gene locus. J Neurochem 70: 2227-2240, 1998

9) Bowman WC: Neuromuscular block. Br J Pharmacol 147(Suppl 1): S277-S286, 2006

10) Cousin MT: Vulpian and not Claude Bernard first proposed the hypothesis of the motor end-palte as the site of action of curare. Anesthesiology 97: 527-528, 2002

11) Walker MB: Treatment of myasthenia gravis with physostigmine. Lancet 1: 1200-1201, 1934

12) Denny-Brown D: Physostigmin and belladonna by mouth in myasthenia gravis. Lancet 225: 767, 1935

13) McAlpine D, Lowe TP: Treatment of myasthenia gravis with "prostigmin". Lancet 225: 516, 1935

14) Laurent LPE: Oral and parenteral administration of prostigmin and its analogues in myasthenia gravis. Lancet 227: 1457-1459, 1936

15) Masuda T, Motomura M, Utsugisawa K, Nagane Y, Nakata R, et al: Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis. J Neurol Neurosurg Psychiatry 83: 935-940, 2012

16) Lee CW, Zhang H, Geng L, Peng HB: Crosslinking-induced endocytosis of acetylcholine receptors by quantum dots. PLOS ONE 9: e90187, 2014

17) 日本神経治療学会・日本神経免疫合同神経免疫疾患治療ガイドライン委員会: 重症筋無力症（Myasthenia gravis: MG）の治療ガイドライン. 神経免疫疾患治療ガイドライン, 2004

18) Kaminski HJ, Kusner LL, Block CH: Expression of acetylcholine receptor isoforms at extraocular muscle endplates. Invest Ophthalmol Vis Sci 37: 345-351, 1996

19) Fraterman S, Khurana TS, Rubinstein NA: Identification of acetylcholine receptor subunits differentially expressed in singly and multiply innervated fibers of extraocular muscles. Invest Ophthalmol Vis Sci 47: 3828-3834, 2006

20) Kaminski HJ, Maas E, Spiegel P, Ruff RL: Why are eye muscles frequently involved in myasthenia gravis? Neurology 40: 1663-1669, 1990

21) Konno S, Ichijo T, Murata M, Toda T, Nakazora H, et al: Autoimmune polyglandular syndrome type 2 with myasthenia gravis crisis. Neurologist 15: 361-363, 2009

22) Wakata N, Sumiyoshi S, Tagaya N, Okada S, Araki Y, et al: A case of myasthenia gravis accompanied by invasive thymoma, alopecia areata and dry mouth. Clin Neurol Neurosurg 97: 161-163, 1995

23) Suzuki S, Utsugisawa K, Suzuki N: Overlooked non-motor symptoms in myasthenia gravis. J Neurol Neurosurg Psychiatry 84: 989-994, 2013

24) 藤岡俊樹, 石田哲朗, 栗原照幸, 木下真男: 重症筋無力症に多発性硬化症が合併し, 抗カルジオリピン抗体が陽性であった1例. 臨床神経33: 572-574, 1993

25) Padua L, Caliandro P, Di Iasi G, Pazzaglia C, Ciaraffa F, et al: Reliability of SFEMG in diagnosing myasthenia gravis: sensitivity and specificity calculated on 100 prospective cases. Clin Neurophysiol, 2013 Nov 15 ［Epub ahead of print］

26) 槍沢公明: 重症筋無力症. 山口　徹, 北原光夫（監): 今日の治療指針2014．医学書院, 東京, 2014, pp894-895

27) Mitsui T, Kuroda Y, Ueno S, Kaji R: The effects of FK506 on refractory inflammatory myopathies. Acta Neurol Belg 111: 188-194, 2011

28) Mitsui T, Kuroda Y, Ueno S, Matsui N, Kaji R: FK506 attenuates thymic output in patients with myasthenia gravis. Arch Med Sci 9: 1090-1096, 2013

29) Pedersen EG, Pottegard A, Hallas J, Friis S, Hansen K, et al: Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark. Eur J Neurol 20: 942-948, 2013

30) 藤岡俊樹: 神経筋疾患の血液浄化療法. 山口　徹, 北原光夫（監): 今日の治療指針2014．医学書院, 東京. 2014, p82

31) Gajdos P, Chevret S, Toyka KV: Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 12: CD002277, 2012

32) Liew WK, Powell CA, Sloan SR, Shamberger RC, Weldon CB, et al: Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA Neurol, 2014 Mar 3 ［Epub ahead of print］

33) 槍沢公明, 長根百合子, 鈴木重明, 鈴木則宏: 全身型MG治療の到達目標と副腎皮質ステロイド, カルシニューリンインヒビターの使用法. 臨床神経52: 1047-1050, 2012

34) Dalakas MC: Novel future therapeutic options in myasthenia gravis. Autoimmun Rev 12: 936-941, 2013

35) Keung B, Robeson KR, DiCapua DB, Rosen JB, O'Connor KC, et al: Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients. J Neurol Neurosurg Psychiatry 84: 1407-1409, 2013

36) 紺野晋吾: リツキシマブ治療施行経験と提言. 臨床神経53: 1312-1314, 2013

37) Yi JS, Decroos EC, Sanders DB, Weinhold KJ, Guptill JT: Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment. Muscle Nerve 48: 992-993, 2013

38) Collongues N, Casez O, Lacour A, Tranchant C, Vermersch P, et al: Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. Muscle Nerve 46: 687-691, 2012

39) Howard JF, Jr., Barohn RJ, Cutter GR, Freimer M, Juel VC, et al: A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 48: 76-84, 2013

40) Huda R, Tuzun E, Christadoss P: Complement C2 siRNA mediated therapy of myasthenia gravis in mice. J Autoimmun 42: 94-104, 2013

41) Aricha R, Mizrachi K, Fuchs S, Souroujon MC: Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun 36: 135-141, 2011

42) Zhang GX, Xiao BG, Bai XF, van der Meide PH, Orn A, et al: Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J Immunol 162: 3775-3781, 1999

43) Angelini C, Martignago S, Bisciglia M: New treatments for myasthenia: a focus on antisense oligonucleotides. Drug Des Devel Ther 7: 13-17, 2013